C12N 2501/50
Cell markers
Official title: Cell markers; Cell surface determinants
C12N2501/50 (Cell markers) appears on 1,234 US grants and 2,621 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,234
- Published applications
- 2,621
- Assignees
- 964
- Inventors
- 4,270
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 1 | 0 |
| 1997 | 7 | 0 |
| 1998 | 11 | 0 |
| 1999 | 6 | 0 |
| 2000 | 11 | 0 |
| 2001 | 12 | 8 |
| 2002 | 12 | 42 |
| 2003 | 13 | 53 |
| 2004 | 12 | 47 |
| 2005 | 14 | 36 |
| 2006 | 12 | 36 |
| 2007 | 9 | 28 |
| 2008 | 12 | 32 |
| 2009 | 13 | 49 |
| 2010 | 28 | 64 |
| 2011 | 30 | 55 |
| 2012 | 32 | 56 |
| 2013 | 20 | 47 |
| 2014 | 46 | 47 |
| 2015 | 47 | 70 |
| 2016 | 45 | 75 |
| 2017 | 36 | 129 |
| 2018 | 61 | 132 |
| 2019 | 90 | 153 |
| 2020 | 79 | 189 |
| 2021 | 95 | 222 |
| 2022 | 97 | 271 |
| 2023 | 75 | 246 |
| 2024 | 109 | 216 |
| 2025 | 121 | 196 |
| 2026 | 66 | 122 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2501/515Cd3, t-cell receptor complexIndexing code508
- C12N 2501/599With cd designations not provided for elsewhereIndexing code353
- C12N 2501/51B7 moleculesIndexing code310
- C12N 2501/58Adhesion moleculesIndexing code128
- C12N 2501/52Cd40, cd40-ligandIndexing code83
- C12N 2501/59LectinsIndexing code60
- C12N 2501/505Cd4Indexing code53
- C12N 2501/585IntegrinsIndexing code32
All 9 subgroupsShow fewer
Recent patents
- Compositions and methods for haematopoietic stem cell transplantation8 Sep 2026US 12,729,371 B2Fondazione Telethon
- Methods of manufacturing CAR-T cells1 Sep 2026US 12,723,268 B2Crispr Therapeutics AG
- Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof25 Aug 2026US 12,716,055 B2Fibrobiologics, Inc.
- Process for producing donor-batched cells expressing a recombinant receptor11 Aug 2026US 12,703,733 B2Juno Therapeutics, Inc.
- Hematopoietic progenitor cell marker11 Aug 2026US 12,703,852 B2Kyoto University
- Metabolically enhanced vd1 t cells and uses thereof8 Oct 2026US 2026/0308518 A1
- Cd4+ cytotoxic t cells and methods of use thereof8 Oct 2026US 2026/0308522 A1Dana-Farber Cancer Institute, Inc.
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
- Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof8 Oct 2026US 2026/0308529 A1Imagine Pharma LLC
- Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy1 Oct 2026US 2026/0293881 A1Iovance Biotherapeutics, Inc.
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005